TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668574
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg every 8 h
Study: 12668574
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg + ritonavir 100 mg every 12 h
Study: 1866408
Drug: nCPAP-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP-therapy
Study: 1866408
Drug: Theophylline 375-400
Normalized name: theophylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 375-400 mg in the evening
Study: 1866408
Drug: O2-therapy by
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2-therapy by 21/min, by nasal prongs
Study: 6406165
Drug: High-calorie and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie and protein supplement
Study: 27657476
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diuretics (HD)
Study: 27657476
Drug: Low diuretic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low diuretic efficiency (DE)
Study: 27657476
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration
Study: 24312305
Drug: High-exposure group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-exposure group (antimicrobial treatment with piperacillin/tazobactam, meropenem, ciprofloxacin)
Study: 24312305
Drug: Standard-of-care (SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC group, antimicrobial treatment with cefuroxime)
Study: 20374604
Drug: Cosmetic regimen
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic regimen (n = 99): SPF 30 moisturizing lotion with 5% niacinamide, peptides, antioxidants; moisturizing cream with niacinamide and peptides; targeted wrinkle product with niacinamide, peptides, and 0.3% retinyl propionate
Study: 20374604
Drug: Prescription regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription regimen (n = 97): 0.02% tretinoin plus moisturizing SPF 30 sunscreen
Study: 17712656
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 1000 mg, twice daily
Study: 17712656
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 500 mg, twice daily
Study: 10759664
Drug: Terazosin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1-2 mg daily, 0.5 mg twice daily for 2 weeks, then 1 mg twice daily for 2 weeks)
Study: 10759664
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg daily for 4 weeks)
Study: 8997678
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg 1 hour presurgery and 400 mg postsurgery)
Study: 6403962
Drug: Pentobarbital 200
Normalized name: PENTobarbital 200 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 200 mg
Study: 6403962
Drug: Pentobarbital 400
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 400 mg
Study: 6403962
Drug: Pentobarbital 600
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 600 mg
Study: 30264977
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg/day for 4 weeks)
Study: 24621109
Drug: BDP/FF 200/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF 200/12 μg twice daily
Study: 24621109
Drug: FP/S 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/S 500/50 μg twice daily
Study: 21933347
Drug: Bayesian approach
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian approach for lithium drug monitoring
Study: 15191772
Drug: Haemoglobin sub-divided
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin sub-divided by 1.0 g/dL increments
Study: 11589263
Drug: Ketoprofen lysine
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysine salt (KLS) mouthwash (10 mL diluted in 100 mL of water, gargled twice daily for up to 7 days)
Study: 11589263
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (BH) mouthwash (15 mL, 22.5 mg, gargled twice daily for up to 7 days)
Study: 2686744
Drug: Cefixime 100
Normalized name: cefixime 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 100 mg once daily (6 months to 5 years), 200 mg once daily (5 to 10 years), 300 mg once daily (10 to 16 years)
Study: 2686744
Drug: Amoxycillin 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin 62.5 mg tds (6 months to 1 year), 125 mg tds (1 to 7 years), 250 mg tds (7 to 16 years)
Study: 30572072
Drug: Exception from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exception from informed consent (EFIC) implementation strategies including community consultation (CC) and public disclosure (PD) methods.
Study: 30572072
Drug: Community consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community consultation (CC) methods such as social media advertising, random digit dialing surveys, working with city officials, and websites with embedded surveys.
Study: 30572072
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from community consultation (CC) to study approval.
Study: 24341820
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guided antibiotic therapy
Study: 24341820
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with antibiotics at physician's discretion (Control)
Study: 21488594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with fluorouracil and folinic acid (de Gramont protocol)
Study: 21488594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for stage II disease
Study: 15156311
Drug: Acemetacin (ACE)
Normalized name: acemetacin
DrugBank: Acemetacin (DB13783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (ACE) 90 mg bid for 6 weeks
Study: 15156311
Drug: Celecoxib (CEL)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (CEL) 200 mg bid for 6 weeks
Study: 11410698
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) over the abdomen and posterior back muscles in addition to physical therapy for 6 weeks
Study: 11410698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only physical therapy for 6 weeks
Study: 9579280
Drug: Oral tacrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tacrine treatment
Study: 2789364
Drug: Ponsinomycin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsinomycin 800 mg syrup administered during a standard meal
Study: 2789364
Drug: Ponsinomycin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsinomycin 800 mg syrup administered 2 hours before a standard meal
Study: 21814211
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg (titrated to 20 mg for nonresponders)
Study: 21814211
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg (titrated to 32 mg for nonresponders)
Study: 16488084
Drug: Olanzapine, 5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine, 5-20 mg/day
Study: 16488084
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy (pre-study antipsychotic medication)
Study: 324835
Drug: Chlorpropamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (100 mg. O.D.)
Study: 324835
Drug: Tolbutamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (500 mg. b.i.d.)
Study: 324835
Drug: Phenformin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin (50 mg. O.D.)
Study: 324835
Drug: Acetohexamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetohexamide (250 mg. O.D.)
Study: 23530305
Drug: Living Well
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living Well By Faith intervention (8-week program, classes held twice a week including educational workshops and exercise sessions)
Study: 19211452
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 to 325 mg/d)
Study: 19211452
Drug: Aspirin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (any dose)
Study: 16492440
Drug: Fortified maternal
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified maternal milk thickened by 1.5 g of precooked starch per 100 mL of milk (milk B)
Study: 14687309
Drug: CVT‐E002 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT‐E002 (200 mg, oral, twice daily)
Study: 10930901
Drug: OMC 4
Normalized name: Oxymorphone Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC 4 (4 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 6 days b.d. 20 mg omeprazole and placebo antibiotics)
Study: 10930901
Drug: OMC 7
Normalized name: iron bg/vit C/vit B12/stomc 70 mg-150 mg-10 mcg-100 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC 7 (7 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 3 days b.d. 20 mg omeprazole and placebo antibiotics)
Study: 10930901
Drug: OMC 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC 10 (10 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Study: 10930901
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments (OMC 4, OMC 7, OMC 10)
Study: 30715261
Drug: (Peg)IFN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Peg)IFN therapy
Study: 30715261
Drug: G3BP2 G-allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G3BP2 G-allele
Study: 27188919
Drug: Liquid contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid contrast agent
Study: 27188919
Drug: Semisolid contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisolid contrast agent
Study: 27188919
Drug: Liquid contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid contrast agent in patients with severe hiatal hernia
Study: 27188919
Drug: Liquid contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid contrast agent in patients with mild hiatal hernia
Study: 27188919
Drug: Liquid contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid contrast agent in patients with no hiatal hernia
Study: 20307215
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - 1-3 injections of 1.25 mg
Study: 20307215
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVT) - 1-3 injections of 2 mg
Study: 18562489
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy administered subcutaneously at 0.05 mg/kg per day until growth velocity was 1 cm/6 months
Study: 18562489
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy in children with a mutation in PTPN11
Study: 8738857
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g twice daily) concurrent with valproic acid (250 mg)
Study: 8738857
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g twice daily) staggered with valproic acid (250 mg, 3 hours apart)
Study: 8738857
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid alone (250 mg)
Study: 1860196
Drug: streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: streptokinase plus heparin
Study: 1860196
Drug: heparin (when
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin (when begun 12 hours after intravenous thrombolysis)
Study: 10227333
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray
Study: 28431551
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive behavioural therapy (iCBT) intervention
Study: 22111350
Drug: Pentazocine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.3 mg x kg(‐1)
Study: 22111350
Drug: Pentazocine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.6 mg x kg(‐1)
Study: 8311488
Drug: KW-2307 single
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 single administration at 10 mg/m2 escalated to 35 mg/m2
Study: 8311488
Drug: KW-2307 repeated
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 repeated administration at 30 mg/m2 for 4 weeks
Study: 8311488
Drug: KW-2307 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 (both administration types)
Study: 8311488
Drug: KW-2307 single
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 single administration
Study: 8311488
Drug: KW-2307 repeated
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 repeated administration
Study: 25363835
Drug: AQW051, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQW051, administered over a broad dose range (up to 200 mg single dose, 75 mg multiple daily doses)
Study: 2892991
Drug: Topical interferon‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon‐beta (IFN‐beta) gel (10(5) U/g) 4 times daily applied locally during eruptions (about 10 days)
Study: 30566636
Drug: 4 ID
Normalized name: Seequin 4 IDS 4 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ID PEP booster doses of 0.1 mL PCEV
Study: 30566636
Drug: 2 ID
Normalized name: Seequin 2 IDS 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ID PEP booster doses of 0.1 mL PCEV
Study: 30566636
Drug: Primary vaccination
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary vaccination with 2 ID doses of 0.1 mL PCEV
Study: 26782228
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of BioPQQ™ per day for 12 weeks
Study: 21155437
Drug: Rocuronium group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium group (n = 30) received PB with a local anesthetic mixture (Lidocaine 2% + Bupivacaine 0.5%) to which was added 0.06 mg/Kg of rocuronium
Study: 17289893
Drug: PV701 (24x10(9)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PV701 (24x10(9) plaque‐forming units/m2 for the first dose, 120x10(9) plaque‐forming units/m2 for doses 2 to 6)
Study: 16332657
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium (1259 +/- 9 mg/d), high dairy (high/high)
Study: 16332657
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium (1259 +/- 9 mg/d), low dairy (high/low)
Study: 16332657
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium (349 +/- 8 mg/d), low dairy (low/low)
Study: 11959610
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg for 3 days
Study: 11959610
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg for 3 days
Study: 6938019
Drug: estracyt or
Normalized name: Estracyt Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: estracyt or vincristine alone or in combination
Study: 31366352
Drug: Cashew apple
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew apple juice (CAJ) at 3.5 mL/kgBM/day for 4 weeks
Study: 27534738
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg once daily for 12 weeks
Study: 27534738
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK 47.5 mg once daily for 12 weeks
Study: 25994539
Drug: Continuation maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation maintenance therapy with pemetrexed
Study: 17200357
Drug: Post-vaccine immune
Normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-vaccine immune response to MART‐1
Study: 12355941
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy involving intravesical instillation after transurethral resection for superficial bladder cancer
Study: 9747867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-phenylalanine mustard, 5-fluorouracil, and doxorubicin (PAF)
Study: 9747867
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard plus 5-fluorouracil (PF)
Study: 8010083
Drug: Ofl tablets
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofl tablets evaluated by NONMEM
Study: 8010083
Drug: Ofl tablets
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofl tablets evaluated by standard approach
Study: 8010083
Drug: Ofl tablets
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofl tablets evaluated by NONMEM with sparse clinical data
Study: 27630253
Drug: IncobotulinumtoxinA (IBTA)
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA (IBTA) injection
Study: 18581096
Drug: Opiate antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Opiate antagonists (nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day)
Study: 11816482
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg doxorubicin
Study: 11816482
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg epirubicin
Study: 9839100
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A (lispro and NPH injected separately)
Study: 9839100
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B (lispro and NPH mixed in syringe)
Study: 9839100
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group C (human regular insulin and NPH mixed)
Study: 2783702
Drug: Amitriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (up to 75 mg/day)
Study: 2783702
Drug: Alcohol (measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (measured dose)
Study: 12014128
Drug: Electro-acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture treatment for 4 weeks
Study: 12014128
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with clinical treatment plus active and/or passive functional exercise
Study: 29222139
Drug: Losartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (150 mg daily)
Study: 24965303
Drug: exendin(9-39)NH2 (ex9-39)
Normalized name: DesPro38Exendin-4(1-39)-Lys6-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exendin(9-39)NH2 (ex9-39) intravenous infusion
Study: 24965303
Drug: saline intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline intravenous infusion
Study: 22364402
Drug: Long-acting methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting methylphenidate formulation (MPH-ret)
Study: 22364402
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (MPH-IR)
Study: 20585297
Drug: Very Low-Carbohydrate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low-Carbohydrate Diet (VLCD) (<40 g carbohydrate; n=12)
Study: 16376739
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of care at referral (chemotherapy, palliative care, or other supportive care)
Study: 975978
Drug: 5-percent solution
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-percent solution of metaproterenol sulfate (Alupent)
Study: 975978
Drug: 0.5-percent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-percent solution of isoproterenol
Study: 975978
Drug: metaproterenol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: metaproterenol therapy
Study: 14695785
Drug: Cimetidine (CIM)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CIM) administered perioperatively, starting 7 days before surgery and continuing for 10 days after surgery.
Study: 11336170
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha alone (3 MU tiw) or in combination with ribavirin for 6-12 months
Study: 7956281
Drug: Heparin (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (6.0 +/- 0.3 IU/kg/hr)
Study: 7956281
Drug: Both PGI2
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both PGI2 (6.4 +/- 0.3 ng/kg/min) and Heparin (5.0 +/- 0.4 IU/kg/hr)